Page 1 | Search Results | Blood | American Society of Hematology

1-9 of 9

Sort by

Sort Order Select

Journal Articles

Efficacy and Safety of Carfilzomib at 56mg/m 2 with Cyclophosphamide and Dexamethasone (K56Cd) in Newly Diagnosed Multiple Myeloma Patients Followed By ASCT or K56Cd Consolidation: Initial Results of the Phase 2 Cardamon Study

Blood (2019) 134 (Supplement_1): 861.

https://doi.org/10.1182/blood-2019-127992

Published: 2019

Journal Articles

A Randomized Comparison Of Maintenance Therapy With Subcutaneous Rituximab For 2 Years Versus Until Progression In Patients With Indolent Non-Hodgkin’s Lymphoma: Interim Safety Data From The Mabcute Study

Simon Rule, MD, Javier Briones, MD, Angelo Michele Carella, MD, Olivier Casasnovas, MD, Wolney Gois Barreto, MD, Christopher Pocock, PhD, Stuart Osborne, PhD, Rodney Smith, MD, Francesco Zaja, MD

Blood (2013) 122 (21): 3052.

https://doi.org/10.1182/blood.V122.21.3052.3052

Published: 2013

Journal Articles

A Phase I/II Study of Bendamustine, Low-Dose Dexamethasone, and Lenalidomide (BdL) for the Treatment of Patients with Relapsed Multiple Myeloma

Stefano Sacchi, Samantha Pozzi, Stefania Badiali, Attilio Guarini, Carla Mazzone, Alessandro Corso, Donatella Vincelli, Luciano Masini, Pellegrino Musto, Roberto Ria, Giovanni Quarta, Antonio Lazzaro, Antonio Palumbo, Fortunato Morabito

Blood (2012) 120 (21): 1851.

https://doi.org/10.1182/blood.V120.21.1851.1851

Published: 2012

Journal Articles

Involved Field Radiotherapy Versus No Further Treatment in Patients with Clinical Stages IA and IIA Hodgkin Lymphoma and a ‘Negative’ PET Scan After 3 Cycles ABVD. Results of the UK NCRI RAPID Trial

John Radford, Sally Barrington, Nicholas Counsell, Ruth Pettengell, Peter Johnson, Jennie Wimperis, Stewart Coltart, Dominic Culligan, Andrew Lister, Eric Bessell, Anton Kruger, Bilyana Popova, Barry Hancock, Peter Hoskin, Timothy Illidge, Michael O'Doherty

Blood (2012) 120 (21): 547.

https://doi.org/10.1182/blood.V120.21.547.547

Published: 2012

Journal Articles

Severe Pulmonary Adverse Events in Healthy Unrelated Donors of Peripheral Blood Stem Cells Following G-CSF Administration,

Katrin Wetzko, MD, Matthias Blechschmidt, MD, Kristina Hölig, MD, Kirsten Poppe-Thiede, MD, Susanne Ganepola, MD, Roman Fischbach, MD, Rainer Ordemann, MD, Michael Laniado, MD, Bernhard Schulte-Hubbert, MD, Markus Schuler, MD, Livia Cotta, MD, Dietrich Braumann, MD, Gerhard Ehninger, MD, Frank Kroschinsky, MD

Blood (2011) 118 (21): 4057.

https://doi.org/10.1182/blood.V118.21.4057.4057

Published: 2011

Journal Articles

Long Term Treatment with Eculizumab In Paroxysmal Nocturnal Hemoglobinuria (PNH): Sustained Efficacy and Improved Survival

Richard J Kelly, MBChB, MRCP(UK), FRCPath, Anita Hill, MBChB, MRCP(UK), FRCPath, PhD, Lindsay D Mitchell, MBChB, MRCP(UK), FRCPath, Stephen John Richards, PhD, FRCPath, Louise M Arnold, RN, BSc, hons, Gemma L Valters, RN, BSc, hons, Matthew Cullen, MSc, Dena R Cohen, MSc, Walter M Gregory, PhD, Peter Hillmen, MBChB, FRCP, FRCPath, PhD

Blood (2010) 116 (21): 639.

https://doi.org/10.1182/blood.V116.21.639.639

Published: 2010

Journal Articles

3G8 and GMA161, Anti FcγRIII Inhibitory Monoclonal Antibodies in the Treatment of Chronic Refractory ITP. (Summary of 2 Pilot Studies).

Charles T Nakar, MD, James B. Bussel, MD

Blood (2009) 114 (22): 2404.

https://doi.org/10.1182/blood.V114.22.2404.2404

Published: 2009

Journal Articles

First Asia-Pacific Co-Operative Multicenter Multiple Myeloma Clinical Trial: Preliminary Results of the “dtZ”/“DAZZLE” Study.

Gerrard Teoh, MBBS, MMed, (Internal, Medicine), Kihyun Kim, Alok Srivastava, MD, Vasant Pai, Sung-Soo Yoon, MD, Cheolwon Suh, MD, Yeo-Kyeoung Kim

Blood (2009) 114 (22): 4940.

https://doi.org/10.1182/blood.V114.22.4940.4940

Published: 2009

Journal Articles

Rapid Transformation to Aggressive B-Cell Lymphoma, in a Case of Mixed Cellularity Hodgkin Lymphoma Subtype : A Rare Event

Antonio Abbadessa, Salvatore Iaccarino, Giuseppe Monaco, Maria Luigia Vigliotti, Mario Troiano, Enrico Attingenti

Blood (2008) 112 (11): 4831.

https://doi.org/10.1182/blood.V112.11.4831.4831

Published: 2008

NARROW

Efficacy and Safety of Carfilzomib at 56mg/m 2 with Cyclophosphamide and Dexamethasone (K56Cd) in Newly Diagnosed Multiple Myeloma Patients Followed By ASCT or K56Cd Consolidation: Initial Results of the Phase 2 Cardamon Study

A Randomized Comparison Of Maintenance Therapy With Subcutaneous Rituximab For 2 Years Versus Until Progression In Patients With Indolent Non-Hodgkin’s Lymphoma: Interim Safety Data From The Mabcute Study

A Phase I/II Study of Bendamustine, Low-Dose Dexamethasone, and Lenalidomide (BdL) for the Treatment of Patients with Relapsed Multiple Myeloma

Involved Field Radiotherapy Versus No Further Treatment in Patients with Clinical Stages IA and IIA Hodgkin Lymphoma and a ‘Negative’ PET Scan After 3 Cycles ABVD. Results of the UK NCRI RAPID Trial

Severe Pulmonary Adverse Events in Healthy Unrelated Donors of Peripheral Blood Stem Cells Following G-CSF Administration,

Long Term Treatment with Eculizumab In Paroxysmal Nocturnal Hemoglobinuria (PNH): Sustained Efficacy and Improved Survival

3G8 and GMA161, Anti FcγRIII Inhibitory Monoclonal Antibodies in the Treatment of Chronic Refractory ITP. (Summary of 2 Pilot Studies).

First Asia-Pacific Co-Operative Multicenter Multiple Myeloma Clinical Trial: Preliminary Results of the “dtZ”/“DAZZLE” Study.

Rapid Transformation to Aggressive B-Cell Lymphoma, in a Case of Mixed Cellularity Hodgkin Lymphoma Subtype : A Rare Event

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only